Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Molecular Therapy. Methods & Clinical Development
|
March 21, 2018
Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer
Lisa A Santry, Thomas M McAusland, Leonardo Susta, et al.
Molecular Therapy. Methods & Clinical Development
|
February 22, 2019
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Lisa A Santry, Thomas M McAusland, et al.
BMC Biotechnology
|
June 20, 2020
Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification
Lisa A Santry, Renaud Jacquemart, Melissa Vandersluis, et al.
Molecular Therapy. Methods & Clinical Development
|
November 17, 2021
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
Jacob P van Vloten, Jessica A Minott, Thomas M McAusland, et al.
Molecular Therapy. Oncology
|
December 1, 2025
Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models
Jacob G E Yates, Lily Chan, Alyssa E Bogle, et al.
Frontiers in Microbiology
|
February 8, 2024
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer
Lisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cytokine & Growth Factor Reviews
|
September 7, 2020
Tumour vasculature: Friend or foe of oncolytic viruses?
Lisa A Santry, Jacob P van Vloten, Jason P Knapp, et al.
Molecular Therapy Oncolytics
|
February 22, 2021
Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models
Thomas M McAusland, Jacob P van Vloten, Lisa A Santry, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2022
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 8, 2023
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency
Sylvia P Thomas, Jakob M Domm, Jacob P van Vloten, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Molecular Therapy. Methods & Clinical Development
|
March 21, 2018
Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer
Lisa A Santry, Thomas M McAusland, Leonardo Susta, et al.
Molecular Therapy. Methods & Clinical Development
|
February 22, 2019
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Lisa A Santry, Thomas M McAusland, et al.
BMC Biotechnology
|
June 20, 2020
Interference chromatography: a novel approach to optimizing chromatographic selectivity and separation performance for virus purification
Lisa A Santry, Renaud Jacquemart, Melissa Vandersluis, et al.
Molecular Therapy. Methods & Clinical Development
|
November 17, 2021
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
Jacob P van Vloten, Jessica A Minott, Thomas M McAusland, et al.
Molecular Therapy. Oncology
|
December 1, 2025
Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models
Jacob G E Yates, Lily Chan, Alyssa E Bogle, et al.
Frontiers in Microbiology
|
February 8, 2024
Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer
Lisa A Santry, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cytokine & Growth Factor Reviews
|
September 7, 2020
Tumour vasculature: Friend or foe of oncolytic viruses?
Lisa A Santry, Jacob P van Vloten, Jason P Knapp, et al.
Molecular Therapy Oncolytics
|
February 22, 2021
Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models
Thomas M McAusland, Jacob P van Vloten, Lisa A Santry, et al.
Journal for Immunotherapy of Cancer
|
March 17, 2022
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
Jacob P van Vloten, Kathy Matuszewska, Mark A A Minow, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
October 8, 2023
A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency
Sylvia P Thomas, Jakob M Domm, Jacob P van Vloten, et al.
Page
of 1